References

1. Ball P (2000) Quinolone generations: natural history or natural selection? J Antimicrob Chemother 46: 17-24 [CrossRef] [Google Scholar] [PubMed]
2. Paton JH, Reeves DS (1988) Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use. Drugs 36: 193-228 [CrossRef] [Google Scholar] [PubMed]
3. Stein GE, Goldstein EJ (2006) Fluoroquinolones and anaerobes. Clin Infect Dis 42: 1598-1607 [CrossRef] [Google Scholar] [PubMed]
4. Wright DH, Brown GH, Peterson ML, Rotschafer JC (2000) Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46: 669-683 [CrossRef] [Google Scholar] [PubMed]
5. Bambeke VF, Tulkens PM (2009) Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 32: 359-378 [CrossRef] [Google Scholar] [PubMed]
6. Drlica K, Zhao X (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61: 377-392 [Google Scholar] [PubMed]
7. Hiasa H, Shea ME (2000) DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone- DNA ternary complex. J Biol Chem 275: 34780-34786 [CrossRef] [Google Scholar] [PubMed]
8. Aldred KJ, Kerns RJ, Osheroff N (2014) Mechanism of quinolone action and resistance. Biochemistry 53: 1565-1574 [CrossRef] [Google Scholar] [PubMed]
9. Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, et al. Kucers' The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. CRC Press
10. The Sanford Guide To Antimicrobial Therapy (2017) Antimicrobial Therapy. Inc. Sperryville, VA, USA
11. Dalhoff A, Stubbings W, Schubert S (2011) Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine. Antimicrob Agents Chemother 55: 1814-1818 [CrossRef] [Google Scholar] [PubMed]
12. Stubbings W, Leow P, Yong GC, Goh F, Korber-Irrgang B, et al. (2011) In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. Antimicrob Agents Chemother 55: 4394-4397 [CrossRef] [Google Scholar] [PubMed]
13. McKeage K (2015) Finafloxacin: first global approval. Drugs 75: 687-693 [CrossRef] [Google Scholar] [PubMed]
14. Lemaire S, Bambeke VF, Tulkens PM (2011) Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionellapneumophila. Int J Antimicrob Agents 38: 52-59 [CrossRef] [Google Scholar] [PubMed]
15. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ (2015) Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13: 269-284 [CrossRef] [Google Scholar] [PubMed]
16. Barnes KB, Hamblin KA, Richards MI, Laws TR, Vente A, et al. (2017) Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei. Antimicrob Agents Chemother 61: e00082-17 [CrossRef] [Google Scholar] [PubMed]
17. XTORO: HIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all of the information needed to use XTORO safety and effectively. See full prescribing information for XTORO*
18. Patel H, Andresen A, Vente A, Heilmann HD, Stubbings W, et al. (2011) Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers. Antimicrob Agents Chemother 55: 4386-4393 [CrossRef] [Google Scholar] [PubMed]
19. Wagenlehner FM, Wagenlehner CM, Blenk B, Blenk H, Schubert S, et al. (2011) Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose. Chemotherapy 57: 97-107 [CrossRef] [Google Scholar] [PubMed]
20. Genzel GH, Stubbings W, Stîngu CS, Labischinski H, Schaumann R, e al. (2014) Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria. Int J Antimicrob Agents 44: 420-423 [CrossRef] [Google Scholar] [PubMed]